Core Viewpoint - Kewang Pharmaceutical has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor. The company is a clinical-stage biopharmaceutical firm focused on developing next-generation cancer therapies through an in-depth understanding of the tumor microenvironment [1]. Company Overview - Kewang Pharmaceutical is dedicated to creating innovative cancer treatments, with its core product ES102 being an advanced hexavalent OX40 agonist that co-stimulates and activates T cells while reversing Treg cell-induced immunosuppression [1]. - ES102 is one of only two OX40 agonist candidates globally that are in Phase 2 or higher clinical development, with no approved OX40 agonists currently available [1]. Clinical Development - The product is specifically designed for cancer patients who have poor responses to immune checkpoint inhibitors (ICIs) and has demonstrated controllable safety and anti-tumor activity in clinical trials, including those in combination with PD-1 antibodies [1]. - Kewang has completed two Phase 1 clinical trials for ES102 targeting advanced solid tumors in China and plans to initiate a Phase 2 clinical trial in April 2025 for ES102 in combination with Toripalimab for patients with advanced non-small cell lung cancer (NSCLC) [1]. Innovation Pipeline - The company possesses a differentiated innovation pipeline, with five major assets in addition to ES102, including ES014, ES104, and ES009, which are in clinical stages [1]. - Kewang has established a comprehensive drug development engine that spans drug discovery to clinical development, utilizing proprietary antibody discovery platforms such as BiME®, Acebody, and ElpiSource [1].

Core Viewpoint - Kewang Pharmaceutical Group has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor. The company aims to develop next-generation cancer therapies globally, focusing on its core product ES102, an advanced six-valent OX40 agonist currently in clinical development [1][6]. Company Overview - Kewang Pharmaceutical, established in 2017, is a clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies by understanding the tumor microenvironment (TME) [6]. - The core product, ES102, is designed to treat cancer patients who respond poorly to immune checkpoint inhibitors (ICIs) and has shown controllable safety and anti-tumor activity in clinical trials [6][7]. Clinical Development - Since acquiring ES102 from Inhibrx in 2018, Kewang has completed two Phase 1 clinical trials in China for advanced solid tumor patients and has initiated a Phase 2 trial combining ES102 with a PD-1 inhibitor for advanced NSCLC patients [7]. - The company has a differentiated pipeline with five major assets, three of which are in clinical stages, targeting unmet medical needs in major tumor types [7]. Research and Development Capabilities - Kewang has established a comprehensive drug development engine, equipped with proprietary technologies covering the entire R&D cycle from drug discovery to clinical development [8]. - The company has developed multiple proprietary antibody discovery platforms, which are crucial for accelerating drug discovery and improving cost-effectiveness [8]. Strategic Partnerships - Kewang has formed a strategic partnership with AstraZeneca to collaborate on a new bispecific macrophage connector project, potentially earning over $1.7 billion in milestone payments [9]. - The company has also partnered with Partex N.V. to develop a platform for designing new therapeutic antibodies, leveraging AI technology [8]. Financial Overview - For the year 2024, Kewang is projected to generate revenue of RMB 106.566 million from its collaboration with AstraZeneca [10]. - The company reported a loss of RMB 729.508 million for the year 2023, with a significant reduction in losses expected in subsequent periods [10].

Core Viewpoint - Kewang Pharmaceutical Group has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor. The company previously submitted a listing application in June 2024. The core product, ES102, is one of the few OX40 agonists in clinical development, with no OX40 agonists approved globally as of the latest feasible date [1][6]. Company Overview - Kewang Pharmaceutical, established in 2017, is a clinical-stage biopharmaceutical company focused on developing next-generation cancer therapies globally. The company aims to innovate in immuno-oncology by targeting promising pathways and biological targets in cancer biology [6]. - The core product, ES102, is an advanced six-valent OX40 agonist designed to stimulate T cells and reverse immune suppression induced by Treg cells. It is specifically aimed at cancer patients who do not respond well to immune checkpoint inhibitors (ICIs) [6][7]. Clinical Development - Kewang has completed two Phase 1 clinical trials of ES102 in China for advanced solid tumor patients, both as a monotherapy and in combination with PD-1 inhibitors. A Phase 2 clinical trial is set to begin in April 2025, exploring the potential of ES102 in combination therapies [7]. - The company has a differentiated pipeline that includes five major assets, three of which are in clinical stages (ES014, ES104, and ES009), positioning it to capitalize on the rapidly growing oncology market [7]. Research and Development Capabilities - Kewang has established a comprehensive drug development engine that spans the entire R&D cycle, from drug discovery to clinical development. The company has developed proprietary technologies in therapeutic antibody development, including platforms like BiME®, Acebody™, and ElpiSource™ [8]. - A strategic collaboration with Partex N.V., an AI-driven drug discovery company, is set to enhance the development of new therapeutic antibodies and biologics through the ELPITEX platform [8]. Strategic Partnerships - Kewang has formed a strategic partnership with Astellas, a global biopharmaceutical company, to collaborate on a new bispecific macrophage connector project derived from the BiME® platform. This partnership could yield over $1.7 billion in milestone payments if Astellas exercises its options [9]. Financial Performance - For the year ending December 31, 2024, Kewang is projected to generate revenue of RMB 106.566 million from its collaboration with Astellas. The company has reported significant losses, with a projected loss of RMB 729.508 million for 2023 [10].

香港聯合交易所有限公司及證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Elpiscience Biopharmaceuticals, Inc. 科望醫藥集團 （「本公司」） （根據開曼群島法律註冊成立之有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的 要求而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代 表 閣下知悉、接納並向本公司、其獨家保薦人、獨家保薦人兼整體協調人、顧問或包銷團成員表 示同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據於香港公司註冊處處長登記 的本公司招股章程作出投資決定，招股章程的文本於發售期內將可供公眾查閱。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根據本 文件中的資料作出任何投資決定； (b) 在聯交所網站登載本文件或其補充 ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Elpiscience Biopharmaceuticals, Inc. 科望醫藥集團 (the "Company") (Incorporated under the laws of the Cayman Islands with ...

Core Viewpoint - Kewang Pharmaceutical Group has submitted an application for an IPO on the Hong Kong Stock Exchange, aiming to raise funds for drug development and operational needs, despite facing significant financial losses and a lack of profitability [1][2][15]. Company Overview - Kewang Pharmaceutical was founded in 2017, focusing on innovative immunotherapy products for cancer treatment, led by a team of prominent scientists and entrepreneurs [5][9]. - The company has experienced a remarkable increase in valuation, growing 23 times from $24.8 million to approximately $599 million over three and a half years [6][8]. Financial Performance - Kewang Pharmaceutical has reported cumulative losses of 1.712 billion yuan over three years, with no approved commercial products and a projected revenue of 106.566 million yuan in 2024 [12][11]. - The company had cash and cash equivalents of 32.82 million yuan as of the end of 2024, indicating a critical need for additional financing [14][15]. Funding History - The company has completed four rounds of financing, raising a total of $252 million (approximately 1.811 billion yuan) from notable investors, including Eli Lilly Asia Fund and Hillhouse Capital [6][8]. - The funding rounds have significantly increased the company's post-money valuation, reflecting strong investor interest despite its ongoing losses [6][7]. Product Pipeline - Kewang's core product, ES102, is a clinical-stage OX40 agonist antibody aimed at treating cancer patients who do not respond well to immune checkpoint inhibitors, with commercialization expected by 2028 [9][10]. - The company also has multiple pipeline assets, with three in clinical stages, including ES014, a first-in-class dual-specific antibody [10]. Management Compensation - The founders of Kewang Pharmaceutical have received substantial compensation, with total earnings exceeding 42 million yuan over two years, highlighting the disparity between executive pay and company performance [8][9].